Table 3.
Overview of the administered antiphlogistic and immunosuppressive medication.
| Immunosuppressive Medication | Patient Count N (%) |
|---|---|
| 36 (100) | |
| Combination therapy | |
| Aminosalicylates + glucocorticoids | 9 (25) |
| Aminosalicylates + purine nucleoside analogues | 1 (3) |
| Aminosalicylates + monoclonal antibodies | 4 (11) |
| Glucocorticoids + purine nucleoside analogues | 3 (8) |
| Glucocorticoids + monoclonal antibodies | 10 (28) |
| Purine nucleoside analogues + monoclonal antibodies | 1 (3) |
| Aminosalicylates + glucocorticoids + monoclonal antibodies | 1 (3) |
| Aminosalicylates + glucocorticoids + purine nucleoside analogues | 1 (3) |
| Monotherapy | |
| Mesalazine | 3 (8) |
| Prednisolone | 1 (3) |
| Adalimumab | 1 (3) |
| Infliximab | 1 (3) |
Aminosalicylates: Mesalazine, Sulfasalazine; Glucocorticoids: Prednisolone, Hydrocortisone, Budenoside; Purine nucleoside analogues: Azathioprine; Monoclonal antibodies: Vedolizumab, Adalimumab, Infliximab, Golimumab, Ustekinumab.